1. Low-dose, short course alteplase treatment of submassive pulmonary embolism
- Author
-
Douglas R. Rosing, Anthony F. Suffredini, Adam R. Metwalli, Jay N. Lozier, Vandana Sachdev, Richard Chang, Richard M. Sherry, Robert L. Danner, Stanislav Sidenko, and Jason M. Elinoff
- Subjects
Adult ,Male ,medicine.medical_specialty ,medicine.medical_treatment ,Hemorrhage ,030204 cardiovascular system & hematology ,law.invention ,Hemodynamic compromise ,03 medical and health sciences ,Retroperitoneal lymph node dissection ,0302 clinical medicine ,Fibrinolytic Agents ,Randomized controlled trial ,law ,medicine.artery ,medicine ,Humans ,Thrombolytic Therapy ,Short course ,In patient ,030212 general & internal medicine ,Aged ,Aged, 80 and over ,business.industry ,Low dose ,Hematology ,General Medicine ,Middle Aged ,medicine.disease ,United States ,Surgery ,Pulmonary embolism ,Treatment Outcome ,National Institutes of Health (U.S.) ,Tissue Plasminogen Activator ,Practice Guidelines as Topic ,Pulmonary artery ,Female ,Pulmonary Embolism ,business - Abstract
Guidelines-recommend thrombolytic therapy for pulmonary embolism in patients with severe hemodynamic compromise and low risk of bleeding. Thrombolytics in submassive pulmonary embolism have an unfavorable risk/benefit ratio and remain controversial. Based on our experience with extensive, lower extremity thrombi, nine patients with symptomatic, submassive pulmonary embolisms (five medical, four surgical) were treated with low-dose alteplase (
- Published
- 2018
- Full Text
- View/download PDF